Tags

Type your tag names separated by a space and hit enter

Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
J Rheumatol. 2008 Dec; 35(12):2363-71.JR

Abstract

OBJECTIVE

To examine serum concentrations of insulin-like growth factor (IGF-1) and IGF binding protein (IGFBP-3), a major carrier protein for IGF-1, in patients with systemic sclerosis (SSc); and to relate the results to clinical features in SSc.

METHODS

Serum IGF-1 and IGFBP-3 levels in 92 Japanese patients with SSc were measured by ELISA. Expression of IGF-1 and IGFBP-3 messenger RNA (mRNA) in the skin was quantified by real-time reverse transcription-polymerase chain reaction.

RESULTS

Serum IGF-1 and IGFBP-3 levels were significantly elevated in patients with SSc compared with patients with systemic lupus erythematosus or healthy controls. IGF-1 levels were higher in patients with diffuse cutaneous SSc (dcSSc) than in patients with limited cutaneous SSc (lcSSc). Patients with increased IGF-1 levels had more severe skin involvement and pulmonary fibrosis. IGF-1 mRNA was upregulated in the affected skin of patients with SSc. There were no significant differences in serum IGFBP-3 levels between dcSSc and lcSSc. IGFBP-3 levels were not associated with skin thickness and pulmonary fibrosis. Patients with increased IGF-1 or IGFBP-3 had lower frequency of telangiectasia than patients with normal levels.

CONCLUSION

These results suggest that both IGF-1 and IGFBP-3 are involved in the development of SSc. The role of IGF-1 appears to be different from that of IGFBP-3.

Authors+Show Affiliations

Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19004037

Citation

Hamaguchi, Yasuhito, et al. "Elevated Serum Insulin-like Growth Factor (IGF-1) and IGF Binding Protein-3 Levels in Patients With Systemic Sclerosis: Possible Role in Development of Fibrosis." The Journal of Rheumatology, vol. 35, no. 12, 2008, pp. 2363-71.
Hamaguchi Y, Fujimoto M, Matsushita T, et al. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol. 2008;35(12):2363-71.
Hamaguchi, Y., Fujimoto, M., Matsushita, T., Hasegawa, M., Takehara, K., & Sato, S. (2008). Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. The Journal of Rheumatology, 35(12), 2363-71. https://doi.org/10.3899/jrheum.080340
Hamaguchi Y, et al. Elevated Serum Insulin-like Growth Factor (IGF-1) and IGF Binding Protein-3 Levels in Patients With Systemic Sclerosis: Possible Role in Development of Fibrosis. J Rheumatol. 2008;35(12):2363-71. PubMed PMID: 19004037.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. AU - Hamaguchi,Yasuhito, AU - Fujimoto,Manabu, AU - Matsushita,Takashi, AU - Hasegawa,Minoru, AU - Takehara,Kazuhiko, AU - Sato,Shinichi, Y1 - 2008/11/01/ PY - 2008/11/13/pubmed PY - 2009/3/25/medline PY - 2008/11/13/entrez SP - 2363 EP - 71 JF - The Journal of rheumatology JO - J Rheumatol VL - 35 IS - 12 N2 - OBJECTIVE: To examine serum concentrations of insulin-like growth factor (IGF-1) and IGF binding protein (IGFBP-3), a major carrier protein for IGF-1, in patients with systemic sclerosis (SSc); and to relate the results to clinical features in SSc. METHODS: Serum IGF-1 and IGFBP-3 levels in 92 Japanese patients with SSc were measured by ELISA. Expression of IGF-1 and IGFBP-3 messenger RNA (mRNA) in the skin was quantified by real-time reverse transcription-polymerase chain reaction. RESULTS: Serum IGF-1 and IGFBP-3 levels were significantly elevated in patients with SSc compared with patients with systemic lupus erythematosus or healthy controls. IGF-1 levels were higher in patients with diffuse cutaneous SSc (dcSSc) than in patients with limited cutaneous SSc (lcSSc). Patients with increased IGF-1 levels had more severe skin involvement and pulmonary fibrosis. IGF-1 mRNA was upregulated in the affected skin of patients with SSc. There were no significant differences in serum IGFBP-3 levels between dcSSc and lcSSc. IGFBP-3 levels were not associated with skin thickness and pulmonary fibrosis. Patients with increased IGF-1 or IGFBP-3 had lower frequency of telangiectasia than patients with normal levels. CONCLUSION: These results suggest that both IGF-1 and IGFBP-3 are involved in the development of SSc. The role of IGF-1 appears to be different from that of IGFBP-3. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/19004037/Elevated_serum_insulin_like_growth_factor__IGF_1__and_IGF_binding_protein_3_levels_in_patients_with_systemic_sclerosis:_possible_role_in_development_of_fibrosis_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&pmid=19004037 DB - PRIME DP - Unbound Medicine ER -